# EArly Effect of Glucocorticoid on Incidence of Persistent Left BundlE Branch Block (LBBB) Post-TAVR (EAGLE-TAVR Trial)

Study · id `cardio:ct-nct06762145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06762145](<https://clinicaltrials.gov/study/NCT06762145>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06762145

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06762145. Randomized; single masking; primary purpose prevention. Start 2025-01-01 (anticipated); primary completion 2025-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06762145, source copy `cardio:ctgov-nct06762145-2025-01-07`, retrieved 2026-10-26)
- Planned start: 2025-01-01 (anticipated) (ClinicalTrials.gov record NCT06762145, source copy `cardio:ctgov-nct06762145-2025-01-07`, retrieved 2026-10-26)
- Primary completion: 2025-06-30 (anticipated) (ClinicalTrials.gov record NCT06762145, source copy `cardio:ctgov-nct06762145-2025-01-07`, retrieved 2026-10-26)
- Completion: 2025-07-31 (anticipated) (ClinicalTrials.gov record NCT06762145, source copy `cardio:ctgov-nct06762145-2025-01-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06762145, source copy `cardio:ctgov-nct06762145-2025-01-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06762145-2025-01-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: EArly Effect of Glucocorticoid on Incidence of Persistent Left BundlE Branch Block (LBBB) Post-TAVR (EAGLE-TAVR Trial)
- Acronym: EAGLE-TAVR
- Condition: Transcatheter Aortic Valve Replacemen
- Condition: Left Bundle Branch Block
- Intervention (Drug): Methylprednisolone (Corticosteroid)
- Intervention (Drug): Placebo
- Lead sponsor: Xiao-dong Zhuang
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Heart block (`cardio:heart-block`)
- Registry lists this organization as the lead sponsor: Xiao-dong Zhuang (`cardio:org-xiao-dong-zhuang`)

## Provenance

Content hash: 8997ba531c0a13eeb3be63cc6cab9b51868c392e77ad3a4ff08acca727c45d62
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
